Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending November 2009. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility, specifically regarding the US Retirement Savings Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific transaction event rather than comprehensive financial performance.
Material Changes
On November 5, 2009, an increase in the notional allocation of Ordinary share ADRs occurred within the US Retirement Savings Plan following a re-valuation of the cash element. The transaction price was $40.46 per ADR. The filing does not report material changes to the company's overall financial position compared to prior periods.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or discussion of risks and contingencies. It is a compliance notification pursuant to Disclosure and Transparency Rule 3.1.4R(1)(a).
Important Facts for Investors
- The filing reports a re-valuation of the US Retirement Savings Plan resulting in increased notional ADR allocations for specific directors.
- The transaction price for the ADRs was $40.46 on November 5, 2009.
- Directors involved in the transaction include Dr M M Slaoui, Mrs C Bruck Slaoui, Mr E J Gray, Mr W C Louv, and Dr D Pulman.
- This document does not contain quarterly or annual financial results.